Acne Scars: Pathogenesis, Classification and Treatment by Fabbrocini, Gabriella et al.
Hindawi Publishing Corporation
Dermatology Research and Practice
Volume 2010, Article ID 893080, 13 pages
doi:10.1155/2010/893080
Review Article
Acne Scars: Pathogenesis, Classiﬁcation and Treatment
GabriellaFabbrocini,M.C.Annunziata,V.D’Arco, V.De Vita,G.Lodi,
M. C.Mauriello,F.Pastore,andG.Monfrecola
Division of Clinical Dermatology, Department of Systematic Pathology, University of Naples Federico II,
Via Sergio Pansini 5, 80133 Napoli, Italy
Correspondence should be addressed to Gabriella Fabbrocini, gafabbro@unina.it
Received 17 March 2010; Revised 7 September 2010; Accepted 28 September 2010
Academic Editor: Daniel Berg
Copyright © 2010 Gabriella Fabbrocini et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Acne has a prevalence of over 90% among adolescents and persists into adulthood in approximately 12%–14% of cases with
psychological and social implications. Possible outcomes of the inﬂammatory acne lesions are acne scars which, although they can
be treated in a number of ways, may have a negative psychological impact on social life and relationships. The main types of acne
scars are atrophic and hypertrophic scars. The pathogenesis of acne scarring is still not fully understood, but several hypotheses
have been proposed. There are numerous treatments: chemical peels, dermabrasion/microdermabrasion, laser treatment, punch
techniques, dermal grafting, needling and combined therapies for atrophic scars: silicone gels, intralesional steroid therapy,
cryotherapy, and surgery for hypertrophic and keloidal lesions. This paper summarizes acne scar pathogenesis, classiﬁcation and
treatment options.
1.Introduction
Acne has a prevalence of over 90% among adolescents [1]
and persists into adulthood in approximately 12%–14%
of cases with psychological and social implications of high
gravity [2, 3].
All body areas with high concentrations of pilosebaceous
glandsareinvolved,butinparticulartheface,backandchest.
Inﬂammatory acne lesions can result in permanent scars,
the severity of which may depend on delays in treating acne
patients. The prevalence and severity of acne scarring in the
population has not been well studied, although the available
literature is usually correlated to the severity of acne [4].
2133 volunteers aged 18 to 70 from the general population
showed that nearly 1% of people had acne scars, although
only 1 in 7 of these were considered to have “disﬁguring
scars” [5]. Severe scarring caused by acne is associated with
substantialphysicalandpsychologicaldistress,particularlyin
adolescents.
2. Pathogenesis
The pathogenesis of acne is currently attributed to multiple
factors, such as increased sebum production, alteration of
the quality of sebum lipids, androgen activity, proliferation
of Propionibacterium acnes (P. acnes) within the follicle and
follicular hyperkeratinization [6]. Increased sebum excretion
contributes to the development of acne. Neutral and polar
lipidsproducedbysebaceousglandsserveavarietyofrolesin
signal transduction and are involved in biological pathways
[7]. Additionally, fatty acids act as ligands of nuclear
receptors such as PPARs. Sebaceous gland lipids exhibit
direct pro- and anti-inﬂammatory properties, whereas the
induction of 5-lipoxygenase and cyclooxygenase-2 pathways
in sebocytes leads to the production of proinﬂammatory
lipids [8]. Furthermore, hormones like androgens control
sebaceous gland size and sebum secretion. In cell culture,
androgens only promote sebocyte proliferation, whereas
PPARligandsarerequiredfortheinductionofdiﬀerentiation
and lipogenic activity [9]. On the other hand, keratinocytes
and sebocytes may be activated by P. acnes via TLR, CD14,
and CD1 molecules [10]. Pilosebaceous follicles in acne
lesions are surrounded by macrophages expressing TLR2
on their surface. TLR2 activation leads to a triggering of
the transcription nuclear factor and thus the production of
cytokines/chemokines, phenomena observed in acne lesions.
Furthermore, P. acnes induces IL-8 and IL-12 release from
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All these events stimulate the infrainfundibular inﬂam-
matory process, follicular rupture, and perifollicular abscess
formation, which stimulate the wound healing process.
Injury to the skin initiates a cascadeof wound healing events.
Wound healing is one of the most complex biological process
andinvolvessolublechemicalmediators,extracellularmatrix
components, parenchymal resident cells as keratinocytes,
ﬁbroblasts, endothelial cells, nerve cells, and inﬁltrating
blood cells like lymphocytes, monocytes, and neutrophils,
collectively known as immunoinﬂammatory cells. Scars
originate in the site of tissue injury and may be atrophic or
hypertrophic.Thewoundhealingprocessprogressesthrough
3 stages: (1) inﬂammation, (2) granulation tissue formation,
and (3) matrix remodeling [12, 13].
(1) Inﬂammation. Blanching occurs secondary to vaso-
constriction for hemostasis. After the blood ﬂow
has been stopped, vasodilatation and resultant ery-
thema replace vasoconstriction. Melanogenesis may
also be stimulated. This step plays an important
role in the development of postacne erythema
and hyperpigmentation. A variety of blood cells,
including granulocytes, macrophages, neutrophils
lymphocytes, ﬁbroblasts, and platelets, are activated
and release inﬂammatory mediators, which ready
the site for granulation tissue formation [14]. By
examining biopsy specimens of acne lesions from the
back of patients with severe scars and without scars,
Holland et al. found that the inﬂammatory reaction
at the pilosebaceous gland was stronger and had a
longer duration in patients with scars versus those
without; in addition, the inﬂammatory reaction was
slower in those with scars versus patients who did
not develop scars. They showed a strong relationship
between severity and duration of inﬂammation and
the development of scarring, suggesting that treating
early inﬂammation in acne lesions may be the best
approach to prevent acne scarring [15].
(2) Granulation Tissue Formation. Damaged tissues are
repaired and new capillaries are formed. Neu-
trophils are replaced by monocytes that change
into macrophages and release several growth factors
including platelet-derived growth factor, ﬁbroblast
growthfactor,andtransforminggrowthfactorsαand
β, which stimulate the migration and proliferation
of ﬁbroblasts [16]. New production of collagen by
ﬁbroblasts begins approximately 3 to 5 days after the
wound is created. Early on, the new skin composition
is dominated by type III collagen, with a small
percentage (20%) of type I collagen. However, the
balance of collagen types shifts in mature scars
to be similar to that of unwounded skin, with
approximately 80% of type I collagen [17].
(3) Matrix Remodelling. Fibroblasts and keratinocytes
produce enzymes including those that determine the
architecture of the extracellular matrix metallopro-
teinases (MMPs) and tissue inhibitors of MMPs.
MMPs are extracellular matrix (ECM) degrading
enzymes that interact and form a lytic cascade
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Figure 1: Acne scars subtypes.
Figure 2: Icepick scars.
for ECM remodeling [18]. As a consequence, an
imbalance in the ratio of MMPs to tissue inhibitors
of MMPs results in the development of atrophic
or hypertrophic scars. Inadequate response results
in diminished deposition of collagen factors and
formation of an atrophic scar while, if the healing
response is too exuberant, a raised nodule of ﬁbrotic
tissue forms hypertrophic scars [19].
3.Morphology, Histology,andClassiﬁcation
Scarring can occur as a result of damage to the skin during
the healing of active acne. There are two basic types of scar
depending on whether there is a net loss or gain of collagen
(atrophic and hypertrophic scars). Eighty to ninety percent
of people with acne scars have scars associated with a loss of
collagen (atrophic scars) compared to a minority who show
hypertrophic scars and keloids.
3.1. Atrophic Scars. Atrophic acne scars are more common
than keloids and hypertrophic scars with a ratio 3:1. They
have been subclassiﬁed into ice pick, boxcar, and rolling scars
(Figure 1 and Table 1). With atrophic scars, the ice pick type
represents 60%–70% of total scars, the boxcar 20%–30%,
and rolling scars 15%–25% [20].
Icepick: narrow (2mm), punctiform, and deep scars are
known as icepick scars. With this type of scar, the opening
is typically wider than the deeper infundibulum (forming a
“V” shape) (Figure 2).Dermatology Research and Practice 3
Table 1: Acne scar morphological classiﬁcation (adapted from [20]).
Acne Scars Subtype Clinical Features
Icepick Icepick scars are narrow (<2mm), deep, sharply marginated epithelial tracts that extend vertically
to the deep dermis or subcutaneous tissue.
Rolling
Rolling scars occur from dermal tethering of otherwise relatively normal-appearing skin and are
usually wider than 4 to 5mm. Abnormal ﬁbrous anchoring of the dermis to the subcutis leads to
superﬁcial shadowing and a rolling or undulating appearance to the overlying skin.
Boxcar
Shallow
<3mm diameter
>3mm diameter
Boxcar scars are round to oval depressions with sharply demarcated vertical edges, similar to
varicella scars. They are clinically wider at the surface than icepick scars and do not taper to a
point at the base.
Deep
<3mm diameter
>3mm diameter
They may be shallow (0.1–0.5mm) or deep (≥0.5mm) and are most often 1.5 to 4.0mm in
diameter.
Figure 3: Boxcar scars.
Rolling: dermal tethering of the dermis to the subcutis
characterizes rolling scars, which are usually wider than 4 to
5mm. These scars give a rolling or undulating appearance to
the skin (“M” shape). Boxcar: round or oval scars with well-
established vertical edges are known as boxcar scars. These
scars tend to be wider at the surface than an icepick scar
and do not have the tapering V shape. Instead, they can be
visualized as a “U” shape with a wide base. Boxcar scars can
be shallow or deep (Figure 3).
Sometimes the 3 diﬀerent types of atrophic scars can
be observed in the same patients and it can be very
diﬃcult to diﬀerentiate between them. For this reason
several classiﬁcations and scales have been proposed by other
authors. Goodman and Baron proposed a qualitative scale
and then presented a quantitative scale [21, 22]. Dreno et
al.introducedtheECCAscale(Echelled’EvaluationClinique
des Cicatrices d’Acn´ e) [23].
The qualitative scarring grading system proposed by
GoodmanandBaron[9]issimpleanduniversallyapplicable.
According to this classiﬁcation, four diﬀerent grades can be
used to identify an acne scar, as shown in Table 2.O f t e n
(especially in those aﬀected with mild acne) the pattern and
grading is easy to achieve but, in the observation of severe
cases, diﬀerent patterns are simultaneously present and may
be diﬃcult to diﬀerentiate. The standard approach adopted
by Goodman and Baron describes a grading pattern and
theydevelopedaquantitativeglobalacnescarringassessment
tool [22] based on the type of scar and the number of
scars. This system assigns fewer points to macular and mild
atrophic scores than to moderate and severe atrophic scores
(macular or mildly atrophic: 1 point; moderately atrophic: 2
points;punchedoutorlinear-troughedseverescars:3points;
hyperplastic papular scars: 4 points). The multiplication
factor for these lesion types is based on the numerical range
whereby, for one to ten scars, the multiplier is 1; for 11–20 it
i s2 ;f o rm o r et h a n2 0i ti s3 .
The ECCA (Echelle d’Evaluation clinique des Cicatrices
d’acn´ e) for facial acne scarring is also a quantitative scale,
designed for use in clinical practice with the aim of
standardizing discussion on scar treatment and it is based
on the sum of individual types of scars and their numerical
extent. Scar types considered to be more visibly disﬁguring
were weighted more heavily. Speciﬁc scar types and their
associated weighting factors were the following: atrophic
scars with diameter less than 2mm: 15; U-shaped atrophic
scars with a diameter of 2–4mm: 20; M-shaped atrophic
scarswithdiametergreaterthan4mm:25;superﬁcialelastol-
ysis: 30; hypertrophic scars with a less than 2-year duration:
40; hypertrophic scars of greater than 2-year duration: 50.
A semiquantitative assessment of the number of each of
these scar types was then determined with a four-point scale,
in which 0 indicates no scars, 1 indicates less than ﬁve
scars, 2 indicates between ﬁve and 20 scars, and 3 indicates
more than 20 scars. With this method, the relative extent of
scarring for each scar type was calculated. The total score
can vary from 0 to 540. In recent studies on the reliability
of this scale, seven dermatologists underwent a 30-min
training session prior to the evaluation of ten acne patients.
There was no statistical diﬀerence in score grading between
participating dermatologists. The global scores, however,
varied from a minimum of 15 to a maximum of 145.
Unfortunately, a statistical estimate of reliability within and
between raters was not provided. The potential advantages
of this system include independent accounting of speciﬁc
scar types, thereby providing for separate atrophic and
hypertrophic subscores in addition to total scores. Potential
shortcomings include restriction to facial involvement, time
intensity,andundeterminedclinicalrelevanceofscoreranges
[21].4 Dermatology Research and Practice
Table 2: Qualitative scarring grading system (adapted from [21]).
Grades of Post
Acne Scarring Level of disease Clinical features
1M a c u l a r
These scars can be erythematous, hyper- or hypopigmented ﬂat marks.
They do not represent a problem of contour like other scar grades but of
color.
2 Mild
Mild atrophy or hypertrophy scars that may not be obvious at social
distances of 50cm or greater and may be covered adequately by makeup or
the normal shadow of shaved beard hair in men or normal body hair if
extrafacial.
3M o d e r a t e
Moderate atrophic or hypertrophic scarring that is obvious at social
distances of 50cm or greater and is not covered easily by makeup or the
normal shadow of shaved beard hair in men or body hair if extrafacial, but
is still able to be ﬂattened by manual stretching of the skin (if atrophic).
4S e v e r e
Severe atrophic or hypertrophic scarring that is evident at social distances
greater than 50cm and is not covered easily by makeup or the normal
shadow of shaved beard hair in men or body hair if extrafacial and is not
able to be ﬂattened by manual stretching of the skin.
3.2. Hypertrophic and Keloidal Scars. Hypertrophic and
keloidal scars are associated with excess collagen deposi-
tion and decreased collagenase activity. Hypertrophic scars
are typically pink, raised, and ﬁrm, with thick hyalinized
collagen bundles that remain within the borders of the
original site of injury. The histology of hypertrophic scars
is similar to that of other dermal scars. In contrast, keloids
form as reddish-purple papules and nodules that proliferate
beyond the borders of the original wound; histologically,
theyarecharacterizedbythickbundlesofhyalinizedacellular
collagen arranged in whorls. Hypertrophic and keloidal scars
are more common in darker-skinned individuals and occur
predominantly on the trunk.
4. Treatment
New acquisitions by the literature have showed that preven-
tion is the main step in avoiding the appearance of post-acne
scars. Genetic factors and the capacity to respond to trauma
are the main factors inﬂuencing scar formation [24]. A
number of treatments are available to reduce the appearance
of scars. First, it is important to reduce as far as possible the
duration and intensity of the inﬂammation, thus stressing
the importance of the acne treatment. The use of topical
retinoids is useful in the prevention of acne scars but more
than any other measure, the use of silicone gel has a proven
eﬃcacyinthepreventionofscars,especiallyforhypertrophic
scars and keloids.
4.1. Atrophic Scars
4.1.1. Chemical Peels. By chemical peeling we mean the
process of applying chemicals to the skin to destroy the outer
damaged layers and accelerate the repair process [25].
Chemical peeling is used for the reversal of signs of skin
a g i n ga n df o rt h et r e a t m e n to fs k i nl e s i o n sa sw e l la ss c a r s ,
particularly acne scars. Dyschromias, wrinkles, and acne
scars are the major clinical indications for facial chemical
peeling [26, 27].
As regards acne scars, the best results are achieved in
macular scars. Icepick and rolling scars cannot disappear
completelyandneedsequentialpeelingstogetherwithhome-
caretreatmentwithtopicalretinoidsandalphahydroxyacids
[28, 29]. The level of improvement expected is extremely
variable in diﬀerent diseases and patients. For example, ice
pick acne scars in a patient with hyperkeratotic skin are only
mildly improved even if skin texture is remodeled. On the
other hand, a patient with isolated box scars can obtain a
signiﬁcant improvement by application of TCA at 50%–90%
on the single scars.
Several hydroxy acids can be used.
(A) Glycolic Acid. Glycolic acid is an alpha-hydroxy acid,
soluble in alcohol, derived from fruit and milk sugars. Gly-
colic acid acts by thinning the stratum corneum, promoting
epidermolysisanddispersingbasallayermelanin.Itincreases
dermal hyaluronic acid and collagen gene expression by
increasing secretion of IL-6 [30]. The procedure is well tol-
erated and patient compliance is excellent, but glycolic acid
peels are contraindicated in contact dermatitis, pregnancy,
and in patients with glycolate hypersensitivity. Side eﬀects,
such as temporary hyperpigmentation or irritation, are not
very signiﬁcant [31]. Some studies showed that the level of
skin damage with glycolic acid peel increases in a dose- and
time-dependent manner. The acid at the higher concentra-
tion (70%) created more tissue damage than the acid at the
lower concentration (50%) compared to solutions with free
acid. An increase in the transmembrane permeability coeﬃ-
cient is observed with a decrease in pH, providing a possible
explanation for the eﬀectiveness of glycolic acid in skin treat-
ment[32].Thebestresultsachievedforacnescarsregardﬁve
sequential sessions of 70% glycolic acid every 2 weeks.
(B) Jessner’s Solution. Formulated by Dr. Max Jessner, this
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in 95% ethanol is an excellent superﬁcial peeling agent.
Resorcinol is structurally and chemically similar to phenol. It
disrupts the weak hydrogen bonds of keratin and enhances-
penetration of other agents [33]. Lactic acid is an alpha
hydroxy acid which causes corneocyte detachment and
subsequent desquamation of the stratum corneum [34].
As with other superﬁcial peeling agents, Jessner’s peels
are well tolerated. General contraindications include active
inﬂammation, dermatitis or infection of the area to be
treated, isotretinoin therapy within 6 months of peeling
and delayed or abnormal wound healing. Allergic contact
dermatitis and systemic allergic reactions to resorcinol are
rare and need to be considered as absolute contraindications
[35, 36].
(C) Pyruvic Acid. Pyruvic acid is an alpha-ketoacid and
an eﬀective peeling agent [37]. It presents keratolytic,
antimicrobial and sebostatic properties as well as the ability
to stimulate new collagen production and the formation of
elastic ﬁbers [38]. The use of 40%–70% pyruvic acid has
been proposed for the treatment of moderate acne scars
[39, 40]. Side eﬀects include desquamation, crusting in areas
of thinner skin, intense stinging, and a burning sensation
during treatment. Pyruvic acid has stinging and irritating
vapors for the upper respiratory mucosa, and it is advisable
to ensure adequate ventilation during application.
(D) Salicylic Acid. Salicylic acid is one of the best peeling
agentsforthetreatmentofacnescars[41].Itisabetahydroxy
acid agent which removes intercellular lipids that are cova-
lently linked to the corniﬁed envelope surrounding corniﬁed
epithelioid cells. The most eﬃcacious concentration for acne
scars is 30% in multiple sessions, 3–5 times, every 3-4 weeks
[42–44]. The side eﬀects of salicylic acid peeling are mild and
transient. These include erythema and dryness. Persistent
postinﬂammatory hyperpigmentation or scarring are very
rare and for this reason it is used to treat dark skin [45].
Rapid breathing, tinnitus, hearing loss, dizziness, abdominal
cramps, and central nervous system symptoms characterize
salicylism or salicylic acid toxicity. This has been observed
with 20% salicylic acid applied to 50% of the body surface
[46]. Grimes has peeled more than 1,000 patients with the
current 20 and 30% marketed ethanol formulations and has
observed no cases of salicylism [47].
( E )T r i c h l o r o a c e t i cA c i d .The use of trichloroacetic acid
(TCA) as a peeling agent was ﬁrst described by P.G. Unna, a
German dermatologist, in 1882. TCA application to the skin
causesproteindenaturation,theso-calledkeratocoagulation,
resulting in a readily observed white frost [48]. For the
purposes of chemical peeling, it is mixed with 100mL
of distilled water to create the desired concentration. The
degree of tissue penetration and injury by a TCA solution
is dependent on several factors, including percentage of
TCA used, anatomic site, and skin preparation. Selection
of appropriate TCA-concentrated solutions is critical when
performing a peel. TCA in a percentage of 10%–20% results
in a very light superﬁcial peel with no penetration below the
stratum granulosum; a concentration of 25%–35% produces
a light superﬁcial peel with diﬀusion encompassing the full
thickness of the epidermis; 40%–50% can produce injury to
the papillary dermis; and ﬁnally, greater than 50% results
in injury extending to the reticular dermis. Unfortunately
the use of TCA concentrations above 35% TCA can produce
unpredictable results such as scarring. Consequently, the
medium depth chemical peel should only be obtained with
the combination of 35% TCA. The use of TCA in con-
centrations greater than 35%, should be avoided. It can be
preferred in some cases of isolated lesions or for treatment of
isolated icepick scars (TCA CROSS) [49]. When performed
properly, peeling with TCA can be one of the most satisfying
procedures in acne scar treatment but it is not indicated
for dark skin because of the high risk of hyperpigmentation
[50].
(F)TCACross. Inour experiencethe TCACROSS technique
has shown high eﬃcacy in the case of few isolated scars
on healthy skin. CROSS stands for chemical reconstruction
of skin scars method and involves local serial application
of high concentration TCA to skin scars with wooden
applicators sized via a number 10 blade to a dull point to
approximate the shape of the scar. No local anesthesia or
sedation is needed to perform this technique [51]. Unlike
the reports found in the literature, in which 90% TCA is
suggested, our experiences have shown that a lower TCA
concentration (50%) has similar results and much less
adverse reactions [52]. TCA is applied for a few seconds
until the scar displays a white frosting. Emollients then needs
to be prescribed for the following 7 days and high photo-
protection is required. The procedure should be repeated at
4-week intervals, and each patient receives a total of three
treatments. Our experiences have shown that, compared
with other procedures, this technique can avoid scarring
and reduce the risk of hypopigmentation by sparing the
adjacent normal skin and adnexal structures [53] (Figures 4
and 5).
4.1.2. Dermabrasion/Microdermabrasion. Dermabrasion
and microdermabrasion are facial resurfacing techniques
that mechanically ablate damaged skin in order to promote
reepithelialisation. Although the act of physical abrasion of
the skin is common to both procedures, dermabrasion, and
microdermabrasion employ diﬀerent instruments with a
diﬀerent technical execution [54]. Dermabrasion completely
removes the epidermis and penetrates to the level of the
papillary or reticular dermis, inducing remodeling of the
skin’s structural proteins. Microdermabrasion, a more
superﬁcial variation of dermabrasion, only removes the
outer layer of the epidermis, accelerating the natural process
of exfoliation [55, 56]. Both techniques are particularly
eﬀective in the treatment of scars and produce clinically
signiﬁcant improvements in skin appearance. Dermabrasion
is performed under local or general anaesthesia. A motorized
hand piece rotates a wire brush or a diamond fraise. Several
d e c a d e sa g o ,t h eh a n dp i e c ew a sm a d eo fa l u m i n u mo x i d eo r
sodiumbicarbonatecrystals,whereasnowdiamondtipshave
replaced these hand pieces to increase accuracy and decrease
irritation. There is often a small pinpoint bleeding of the raw6 Dermatology Research and Practice
Figure 4: TCA Cross: patient before the treatment.
Figure 5: TCA Cross: patient after the treatment.
wound that subsides with appropriate wound care. Patients
with darker skin may experience permanent skin discol-
oration or blotchiness. As regards the technique of microder-
mabrasion, a variety of microdermabraders are available. All
microdermabraders include a pump that generates a stream
of aluminum oxide or salt crystals with a hand piece and
vacuum to remove the crystals and exfoliate the skin [57].
Unlike dermabrasion, microdermabrasion can be repeated
at short intervals, is painless, does not require anesthesia
and is associated with less severe and rare complications,
but it also has a lesser eﬀect and does not treat deep scars
[58, 59].
It is essential to conduct a thorough investigation of the
patient’s pharmacological history to ensure that the patient
has not taken isotretinoin in the previous 6–12 months.
As noted by some studies [60], the use of tretinoin causes
delayed reepithelialization and development of hypertrophic
scars.
4.1.3. Laser Treatment. All patients with box-car scars
(superﬁcial or deep) or rolling scars are candidates for laser
treatment. Diﬀerent types of laser, including the nonablative
and ablative lasers are very useful in treating acne scars.
Ablative lasers achieve removal of the damaged scar tissue
through melting, evaporation, or vaporization. Carbon
dioxide laser and Erbium YAG laser are the most commonly
used ablative lasers for the treatment of acne scars. These
abrade the surface and also help tighten the collagen ﬁbers
beneath. Nonablative lasers do not remove the tissue, but
stimulate new collagen formation and cause tightening of
the skin resulting in the scar being raised to the surface.
Among the nonablative lasers the most commonly used are
the NdYAG and Diode lasers [61].
Theablative lasersaretechnologies withahighselectivity
for water. Therefore, their action takes place mainly on the
surface but the depth of action is certainly to be correlated to
the intensity of the emitted energy and the diameter of the
spot used. Among the ablative lasers, Erbium technologies
aresoselectiveforwaterthattheiractionisalmostexclusively
ablative.CO2 lasers,whichpresentlowerselectivityforwater,
besides causing ablation are also capable of determining
a denaturation in the tissues surrounding the ablation
and a thermal stimulus not coagulated for dermal protein.
CO2 lasers have a double eﬀect: they promote the wound
healing process and arouse an ampliﬁed production of
myoﬁbroblasts and matrix proteins such as hyaluronic acid
[62].
Clinical and histopathologic studies have previously
demonstrated the eﬃcacy of CO2 laser resurfacing in the
improvement of facial atrophic acne scars, with a 50%–
80% improvement typically seen. The diﬀerences in results
reported with apparently similar laser techniques may be
due to variations in the types of scar treated. Candidates
must present a skin disease with acne oﬀ for at least 1 year;
they should have stopped taking oral isotretinoin for at least
1 year; they should not have presented skin infections by
herpes virus during the six months prior to treatment; they
must not have a history of keloids or hypertrophic scarring.
Patients with a high skin type phototype are exposed to
a higher risk of hyperpigmentation after treatment than
patients with low phototype.
All ablative lasers showed high risk of complications
and side eﬀects. Adverse reactions to the ﬁrst generation of
ablative lasers can be classiﬁed into short-term (bacterial,
herpetic or fungal infections) and long-term (persistent ery-
thema, hyperpigmentation, scarring) [63, 64]. In particular,
scarring after CO2 laser therapy may be due to the over
treatment of the areas (including excessive energy, density,
or both), lack of technical aspects, infection, or idiopathic. It
is necessary to take into account these aspects when sensitive
areas such as the eyelids, upper neck, and especially the lower
neck and chest are treated [65, 66].
Nonablative skin remodeling systems have become
increasingly popular for the treatment of facial rhytides
and acne scars because they decrease the risk of side
eﬀects and the need for postoperative care. Nonablative
technology using long-pulse infrared (1.450nm diode, 1320
and 1064nm neodymium-doped yttrium aluminum garnet
(Nd:YAG), and 1540nm erbium glass) was developed as
a safe alternative to ablative technology for inducing a
controlled thermal injury to the dermis, with subsequent
neocollagenesis and remodeling of scarred skin [67–72].
Althoughimprovementwasnotedwiththesenonablative
lasers, the results obtained were not as impressive as the
results from those using laser resurfacing [71].
For this reason, a new concept in skin laser therapy,
called fractional photothermolysis, has been designed toDermatology Research and Practice 7
create microscopic thermal wounds to achieve homogeneous
thermal damage at a particular depth within the skin,
a method that diﬀe r sf r o mc h e m i c a lp e e l i n ga n dl a s e r
resurfacing. Prior studies using fractional photothermolysis
have demonstrated its eﬀectiveness in the treatment of acne
scars [73] with particular attention for dark skin to avoid
postinﬂammatory hyperpigmentation [74].
Newer modalities using the principles of fractional
p h o t o t h e r m o l y s i sd e v i c e s( F P )t oc r e a t ep a t t e r n so ft i n y
microscopic wounds surrounded by undamaged tissues are
new devices that are preferred for these treatments. These
devices produce more modest results in many cases than
traditional carbon dioxide lasers but have few side eﬀects
and short recovery periods [75]. Many fractional lasers
are available with diﬀerent types of source. A great deal
of experience with nonablative 1550nm erbium doped
fractional photothermolysis has shown that the system can
be widely used for clinical purposes.
Anablative30WCO2 laserdeviceusesablativefractional
resurfacing (AFR) and combines CO2 ablation with an FP
system. By depositing a pixilated pattern of microscopic
ablative wounds surrounded by healthy tissue in a manner
similar to that of FP [76], AFR combines the increased
eﬃcacy of ablative techniques with the safety and reduced
downtime associated with FP.
Topographic analysis performed by some authors has
shown that the depth of acneiform scars has quantiﬁable
objective improvement ranging from 43% to 80% with
a mean level of 66.8% [77]. The diﬀerent experiences
of numerous authors in this ﬁeld have shown that, by
combining ablativetechnology withFP, AFR treatmentscon-
stitute a safe and eﬀective treatment modality for acneiform
scarring. Compared to conventional ablative CO2 devices
the side eﬀects proﬁle is greatly improved and, as with
FP, rapid reepithelization from surrounding undamaged
tissue is believed to be responsible for the comparatively
rapid recovery and reduced downtime noted with AFR
[78–80].
Pigmentation abnormalities following laser treatment is
always a concern. Alster and West reported 36% incidence
of hyperpigmentation when using conventional CO2 resur-
facing compared to a minority of patients treated with AFR
treatments, probably linked to shortened period of recovery
and posttreatment erythema [81]. The treatment strategy
is linked to establishing the optimal energy, the interval
between sessions, and a longer follow-up period to optimize
treatment parameters.
4.1.4. Punch Techniques. Atrophic scarring is the more
commontypeofscarringencounteredafteracne.Autologous
and nonautologous tissue augmentation, and the use of
punchreplacementtechniqueshasaddedmoreprecisionand
eﬃcacy to the treatment of these scars [82].
The laser punch-out method is better than even depth
resurfacing for improving deep acne scars and can be com-
bined with the shoulder technique or even depth resurfacing
according to the type of acne scar [83].
Laser skin resurfacing with the concurrent use of punch
excision improves facial acne scarring [84].
4.1.5. Dermal Grafting. Acne scars may be treated surgically
using procedures such as dermabrasion and/or simple scar
excision, scar punch elevation, or punch grafting [85].
The useful modalities available are dermal punch graft-
ing, excision, and facelifting. The selection of these tech-
niques is dependent on the above classiﬁcation and the
patient’s desire for improvement [86].
Split-thickness or full-thickness grafts “take” on a bed of
scar tissue or dermis following the removal of the epidermis.
The technique is useful in repairing unstable scars from
chronic leg ulcers or X-ray scars. It can also camouﬂage acne
scars, extensive nevi pigmentosus, and tattoos [87, 88]. It is
prepackaged dermal graft material that is easy to use, safe,
and eﬀective [89].
4.1.6. Tissue Augmenting Agents. Fat transplantation. Fat is
easily available and it has low incidence of side eﬀects [90].
The technique consists of two phases: procurement of the
graft and placement of the graft. The injection phase with
small parcels of fat implanted in multiple tunnels allows the
fatgraftmaximalaccesstoitsavailablebloodysupply.Thefat
injected will normalize the contour excepted where residual
scar attachments impede this.
4.1.7. Other Tissue Augmenting Agents. There are many
new and older autologous, nonautologous biologic, and
nonbiologic tissue augmentation agents that have been used
in the past for atrophic scars, such as autologous collagen,
bovine collagen, isolagen, alloderm, hyaluronic acid, ﬁbrel,
artecoll, and silicon, but nowadays, because of the high
incidence of side eﬀects, the recommended material to use
is hyaluronic acid [91].
4.1.8. Needling. Skin needling is a recently proposed tech-
nique that involves using a sterile roller comprised of a
series of ﬁne, sharp needles to puncture the skin. At ﬁrst,
facial skin must be disinfected, then a topical anesthetic is
applied, left for 60 minutes. The skin needling procedure is
achieved by rolling a performed tool on the cutaneous areas
aﬀected by acne scars (Figure 6), backward and forward with
some pressure in various directions. The needles penetrate
about 1.5 to 2mm into the dermis. As expected, the skin
bleeds for a short time, but that soon stops. The skin
develops multiple microbruises in the dermis that initiate
the complex cascade of growth factors that ﬁnally results
in collagen production. Histology shows thickening of skin
and a dramatic increase in new collagen and elastin ﬁbers.
Results generally start to be seen after about 6 weeks but
the full eﬀects can take at least three months to occur and,
as the deposition of new collagen takes place slowly, the
skin texture will continue to improve over a 12 month
period. Clinical results vary between patients, but all patients
achieve some improvements (Figures 7 and 8). The number
of treatments required varies depending on the individual
collagen response, on the condition of the tissue and on the
desired results. Most patients require around 3 treatments
approximately 4 weeks apart. Skin needling can be safely
performed on all skin colours and types: there is a lower8 Dermatology Research and Practice
Figure 6: Needling: the procedure.
Figure 7: Needling: patient before the treatment.
risk of postinﬂammatory hyperpigmentation than other
procedures, such as dermabrasion, chemical peelings, and
laser resurfacing. Skin needling is contraindicated in the
presence of anticoagulant therapies, active skin infections,
collageninjections,andotherinjectableﬁllersintheprevious
six months, personal or familiar history of hypertrophic and
keloidal scars [92, 93].
4.1.9. Combined Therapy. There is a new combination
therapy for the treatment of acne scars. The ﬁrst therapy
consists of peeling with trichloroacetic acid, then followed
by subcision, the process by which there is separation of the
acne scar from the underlying skin and in the end fractional
laser irradiation. The eﬃcacy and safety of this method was
investigated for the treatment of acne scars. The duration
of this therapy is 12 months. Dot peeling and subcision
were performed twice 2-3 months apart and fractional laser
irradiation was performed every 3-4 weeks. There were no
signiﬁcant complications at the treatment sites. It would
appear that triple combination therapy is a safe and very
eﬀective combination treatment modality for a variety of
atrophic acne scars [94].
Figure 8: Needling: patient after the treatment.
4.2. Hypertrophic Scars
4.2.1. Silicone Gel. Silicone-based products represent one of
the most common and eﬀective solutions in preventing and
also in the treatment of hypertrophic acne scars. The silicone
gel was introduced in the treatment of hypertrophic acne
scars to overcome the diﬃculties in the management of sil-
icone sheets. Indeed, the silicone gel has several advantages:
it is transparent, quick drying, nonirritating and does not
induce skin maceration, it can be used to treat extensive
scars and uneven areas of skin. The mechanism of action is
not fully understood but several hypotheses [95]h a v eb e e n
advanced: (1) the increase in hydration; (2) the increase in
temperature; (3) protection of the scar; (4) increased tension
of O2; (5) action on the immune system. There is, currently,
only one observational open label study, conducted on 57
patients. In this study, the gel was applied on the scars 2
times daily for 8 weeks with an average improvement in
the thickness estimated between 40% and 50% compared to
baseline.
As regards the treatment of already formed hypertrophic
scars, the gel should be applied in small amounts, twice daily
for at least 8 weeks to achieve a satisfactory aesthetic result.
Whereas for the purposes of prevention, the same dosage is
recommended for at least 12–16 weeks; the treatment should
be started as soon as possible after the risk of a patient
developing hypertrophic acne scars has been identiﬁed.
Treatment with silicone gel can be used in patients of any
age and women of childbearing age. Moreover, the silicone
gel can be used throughout the year, including summer.
4.2.2. Intralesional Steroid Therapy. Intralesional injection
of steroids is one of the most common treatments for
keloids and hypertrophic scars. It can be used alone or
as part of multiple therapeutic approaches. Corticosteroids
may reduce the volume, thickness, and texture of scars, and
they can relieve symptoms such as itching and discomfort
[96]. The mechanisms of action have not been completely
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it has been suggested that steroids exert a vasoconstrictor
and an antimitotic activity. It is believed that steroids
arrest pathological collagen production through two distinct
mechanisms: the reduction of oxygen and nutrients to the
scar with inhibition of the proliferation of keratinocytes
and ﬁbroblasts [96]; the stimulation of digestion of collagen
deposition through block of a collagenase-inhibitor, the
alpha-2-microglobulin[97].Duringtheinjectionthesyringe
needle should be kept upright [24]. It is always preferable for
the injections to be preceded by the application of anesthetic
creams or be associated with injections of lidocaine [97].
Intralesional steroid therapy may be preceded by a light
cryotherapy with liquid nitrogen, 10–15 minutes before
injection, to improve the dispersion of the drug in scar
tissue and minimize the deposition in the subcutaneous and
perilesional tissue [98]. The steroid that is currently most
frequently used in the treatment of hypertrophic scars and
keloids is triamcinolone acetonide (10–40mg/mL) [99]. The
most common adverse reactions are hypopigmentation, skin
atrophy, telangiectasia, and infections [100]. As for injuries
to the face, the use of intralesional steroids is recommended
for the treatment of individual elements which are
particularly bulky and refractory to previous less invasive
methods.
4.2.3. Cryotherapy. Cryotherapy with liquid nitrogen can
signiﬁcantly improve the clinical appearance of hypertrophic
scars and keloids and also determine their complete regres-
sion.
The low temperatures reached during cryotherapy ses-
sions cause a slowing of blood ﬂow and cause the formation
of intraluminal thrombus hesitant to anoxia and tissue
necrosis [101]. Age and size of the scar are important factors
conditioning the outcome of this technique: younger and
smaller scars are most responsive to cryotherapy [102].
Compared with intralesional injections of corticosteroids,
cryosurgery is signiﬁcantly more eﬀective than alternative
methods for richly vascularized injuries 12 months younger
[103]. During each session of cryotherapy the patient is
usually subjected to 2-3 cycles, each lasting less than 25
seconds. Cryotherapy can also be used before each cycle
of intralesional injections of steroids to reduce the pain of
injection therapy and to facilitate the injection of cortisone,
generating a small area of edema at the level of the scar tissue
to be treated [98]. Possible adverse reactions are represented
by hypo- and hyperpigmentation, skin atrophy, and pain
[102]. With regard to localized lesions to the face, the
possible outcomes of freezing restrict the use of cryotherapy
in these areas, especially in cases where the scars are
numerous or for dark phenotypes. Therefore, cryotherapy
can be taken into consideration especially for scars located
on the trunk or for particularly bulky scars on the face.
4.2.4. Pulsed Dye Laser. The use of lasers for hypertrophic
scars and keloids was ﬁrst proposed by Apfelberg et al.
[104]a n dC a s t r oe ta l .[ 105] in the 1980s, and since then
more lasers with various wavelengths have been introduced.
Unfortunately, laser therapy for hypertrophic scars has
had only variable success in the past due to the minimal
improvement in a high percent of patients [106–108].
On the contrary, the use of pulsed dye laser (PDL) has
provided encouraging results in the treatment of hyper-
trophic/keloidal scars over the past 10 years. Several studies
have been conducted to investigate how the PDL works on
hypertrophic/keloidal scars. They have revealed that PDL
decreases the number and proliferation of ﬁbroblasts and
collagenﬁbersappearlooserandlesscoarse[109]. Moreover,
PDL also produces an increase in MMP-I3 (collagenese-
3) activity and a decrease in collagen type III deposition
[110]. As a consequence, PDL ﬂattens and decreases the
volume of hypertrophic scars [111, 112], improves texture
[113],andincreaseselasticity[114],usuallyaftertwotothree
treatments [115]. Additionally, pruritis and pain within the
scarsaresigniﬁcantlyimproved[116].Besides,norecurrence
or worsening of PDL-treated scars occurs during the 4-
year followup after cessation of treatment [116]. The most
common side eﬀect of the PDL is purpura which can last
as long as 7–10 days. Blistering can also occur as well as
hypo- and hyperpigmentation which is more likely in darker
skinned individuals [117]. Therefore, the ideal candidates
for PDL are patients with lighter skin types (Fitzpatrick
Types I–III) because less melanin is present to compete with
hemoglobin laser energy absorption [118, 119].
4.2.5. Surgery. For the correction of large facial scars, W-
plasty seems to be optimal [12]. This therapeutic procedure
causes a disruption of the scar which makes the lesion
less conspicuous. Especially in facial surgery, autologous
skin transplants, namely, full thickness skin transplant or
composite fat-skin graft, are another valuable alternative
for achieving wound closure with minimal tension. The
preferred donor sites for skin graft used for facial defects are
the retro- and preauricular sites as well as the neck [120].
4.2.6. Other Approaches. Other treatment options for hyper-
trophic acne scars and keloids that can be taken into
account include elastic compression, intralesional injection
of 5-ﬂuorouracil, imiquimod, interferon, radiotherapy, and
bleomycin. All these approaches, however, are more eﬀective
for the treatment of hypertrophic scars not caused by acne
and their use is not recommended due to their impracticality
(elastic compression), the lack of clinical experience in the
literature (5 FU, interferon, radiotherapy, bleomycin) the
lack of eﬃcacy (imiquimod), and the high costs (interferon).
5. Conclusion
There are no general guidelines available to optimize acne
scar treatment. There are several multiple management
options, both medical and surgical, and laser devices are use-
ful in obtaining signiﬁcant improvement. Further primary
research such as randomized controlled trials is needed in
order to quantify the beneﬁts and to establish the duration
of the eﬀects, the cost-eﬀective ratio of diﬀerent treatments,
andtheevaluationofthepsychologicalimprovementandthe
quality of life of these patients.10 Dermatology Research and Practice
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